Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults
Primary Purpose
Influenza
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
MF59 H1N1 vaccine
Plain H1N1 vaccine
Sponsored by
About this trial
This is an interventional prevention trial for Influenza focused on measuring influenza, immunogenicity, vaccine
Eligibility Criteria
Inclusion Criteria:
- Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol.
- Male or female subjects 18-50 years who are either healthy or have a stable medical condition.
- Able to understand and comply with all study procedures and to complete study diaries
- Individuals who can be contacted throughout the study and are available for all study visits
Females should either be using secure contraceptive precautions including:
- the oral contraceptive pill
- condom/barrier contraception
- partner has had a vasectomy
- be surgically sterilised, or
- post-menopausal (defined as at least two years since the last menstrual period)
Exclusion Criteria:
- Any clinically significant concurrent illness or unstable medical condition including: malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or progressive renal or hepatic pathology, chronic obstructive pulmonary disease requiring oxygen therapy, and any active neurological disorder.
- Individuals with a history of anaphylaxis or serious reactions to vaccines; hypersensitivity to influenzal viral protein, neomycin or polymixin, or products containing mercury.
- Persons with known immunosuppressive disease or who use systemic immunosuppressive drugs or other drugs listed in section 8 of the British National Formulary (BNF) or chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF to suppress a chronic disease process, or have received in the last 6 months radiotherapy or chemotherapy.
- Subjects who are at high risk of developing illnesses of the immune system.
- Individuals who are taking immunostimulant therapy or interferon
- Individuals who have received blood products or immunoglobulins parenterally during the preceding three months.
- Women should not be pregnant or lactating.
- Women who refuse to use a reliable contraceptive method throughout the study
- Known or suspected drug abuse.
- Individuals who have received another vaccine or investigational medicinal product in the preceding 2 weeks.
- Unable to lead an independent life either physically or mentally
- Regularly drink more than 40 units of alcohol weekly
- Individuals who have had acute respiratory pathology or infections requiring systemic antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic therapy for prevention of urinary tract infections is acceptable).
- Individuals who had a temperature >38oC in the preceding 3 days.
- Individuals who, in the opinion of the investigator, have conditions that might complicate interpretation of the study results.
- Individuals who have had confirmed pandemic influenza H1 infection
Sites / Locations
- University Hospitals Leicester
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Vaccine
Vaccine 2
Arm Description
adjuvanted influenza vaccine
non-adjuvanted vaccine
Outcomes
Primary Outcome Measures
GMT antibody rises
Secondary Outcome Measures
frequency of adverse reactions
Full Information
NCT ID
NCT00943358
First Posted
July 20, 2009
Last Updated
August 7, 2012
Sponsor
University Hospitals, Leicester
Collaborators
Public Health England, Novartis Vaccines
1. Study Identification
Unique Protocol Identification Number
NCT00943358
Brief Title
Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults
Official Title
Safety and Immunogenicity of Cell-culture Non-adjuvanted and MF59-adjuvanted Influenza H1N1 Vaccines in Healthy Adults
Study Type
Interventional
2. Study Status
Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospitals, Leicester
Collaborators
Public Health England, Novartis Vaccines
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the antibody response to one and two doses of influenza A/H1N1v vaccine in healthy adults.
Detailed Description
An observer-blind, single-centre study in which 7 groups of 25-30 male and female adults ≥18-50 years of age will be randomly allocated to receive two doses of cell culture non-adjuvanted or MF59-adjuvanted influenza A/California/4/2009 (H1N1) surface antigen vaccine containing 3.75, 7.5 or 15µg haemagglutinin by intramuscular injection. A second dose of the same vaccine containing the same quantity of antigen as in the first dose will be administered 21 days later. Three additional groups will receive two doses of MF59-adjuvanted influenza A/California/4/2009 (H1N1) surface antigen vaccine containing 7.5 µg haemagglutinin by intramuscular injection on day 0 or separated by 7 or 14 days. Subjects will be observed for local and systemic reactions for 30 minutes after each immunisation and will be monitored for any reactions and other adverse events for 7 days after each immunisation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
influenza, immunogenicity, vaccine
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
175 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vaccine
Arm Type
Active Comparator
Arm Description
adjuvanted influenza vaccine
Arm Title
Vaccine 2
Arm Type
Active Comparator
Arm Description
non-adjuvanted vaccine
Intervention Type
Biological
Intervention Name(s)
MF59 H1N1 vaccine
Intervention Description
3.75-7.5ug dose
Intervention Type
Biological
Intervention Name(s)
Plain H1N1 vaccine
Intervention Description
7.5-15ug
Primary Outcome Measure Information:
Title
GMT antibody rises
Time Frame
42 days
Secondary Outcome Measure Information:
Title
frequency of adverse reactions
Time Frame
42 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol.
Male or female subjects 18-50 years who are either healthy or have a stable medical condition.
Able to understand and comply with all study procedures and to complete study diaries
Individuals who can be contacted throughout the study and are available for all study visits
Females should either be using secure contraceptive precautions including:
the oral contraceptive pill
condom/barrier contraception
partner has had a vasectomy
be surgically sterilised, or
post-menopausal (defined as at least two years since the last menstrual period)
Exclusion Criteria:
Any clinically significant concurrent illness or unstable medical condition including: malignant tumours, autoimmune illnesses (including rheumatoid arthritis), acute or progressive renal or hepatic pathology, chronic obstructive pulmonary disease requiring oxygen therapy, and any active neurological disorder.
Individuals with a history of anaphylaxis or serious reactions to vaccines; hypersensitivity to influenzal viral protein, neomycin or polymixin, or products containing mercury.
Persons with known immunosuppressive disease or who use systemic immunosuppressive drugs or other drugs listed in section 8 of the British National Formulary (BNF) or chloroquine, gold or penicillamine or other drugs listed in section 10.1.3 of the BNF to suppress a chronic disease process, or have received in the last 6 months radiotherapy or chemotherapy.
Subjects who are at high risk of developing illnesses of the immune system.
Individuals who are taking immunostimulant therapy or interferon
Individuals who have received blood products or immunoglobulins parenterally during the preceding three months.
Women should not be pregnant or lactating.
Women who refuse to use a reliable contraceptive method throughout the study
Known or suspected drug abuse.
Individuals who have received another vaccine or investigational medicinal product in the preceding 2 weeks.
Unable to lead an independent life either physically or mentally
Regularly drink more than 40 units of alcohol weekly
Individuals who have had acute respiratory pathology or infections requiring systemic antibiotic or antiviral therapy during the preceding 7 days (chronic antibiotic therapy for prevention of urinary tract infections is acceptable).
Individuals who had a temperature >38oC in the preceding 3 days.
Individuals who, in the opinion of the investigator, have conditions that might complicate interpretation of the study results.
Individuals who have had confirmed pandemic influenza H1 infection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Iain Stephenson, FRCP
Organizational Affiliation
University Hospitals, Leicester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Leicester
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
19745215
Citation
Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10.
Results Reference
derived
Learn more about this trial
Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults
We'll reach out to this number within 24 hrs